Qilu Pharmaceutical's Aflibercept Biosimilar Approved as First Domestic Version in China
Qilu Pharmaceutical
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer
On December 18, according to the NMPA official website, Qilu Pharmaceutical's aflibercept biosimilar was approved for marketing, becoming the first domestically produced one in China.
Source: NMPA Official Website
Aflibercept intravitreal injection solution is a fully humanized fusion protein that can simultaneously block VEGF-A, VEGF-B, and PIGF, with a broader range of action targets; it can bind more effectively to VEGF dimers; meanwhile, it has a longer duration of action and provides more sustained efficacy.For the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Aflibercept isByRegeneronAndDeveloped in collaboration with Bayer, onApproved by the FDA for marketing in November 2011 under the trade name Eylea, and approved for marketing in China in February 2018.Currently, the intravitreal injection solution of aflibercept has been approved for marketing in many countries around the world.The multi-billion dollar market for aflibercept has also attracted the attention of more companies in China. Currently, apart from Qilu Pharmaceutical Co., Ltd., there are others.Jingze Biotech, Mabwell Biotech, etc.Chinese companies are also laying out plans for biosimilar versions of Aflibercept.
